A Phase 1 Study of Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Magrolimab (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions
- Acronyms VENOM
- 13 Feb 2024 Planned primary completion date changed from 8 Feb 2026 to 29 Mar 2024.
- 09 Feb 2024 Planned End Date changed from 26 Jun 2028 to 8 Feb 2027.
- 09 Feb 2024 Planned primary completion date changed from 30 Dec 2026 to 8 Feb 2026.